Erythropoietin does not affect nitric oxide system in rats with chronic renal failure

Journal of Korean Medical Science

Volumn 15, Issue 2, 2000, Pages 183-188

  Kim, Soo Wan ^a   Lee, JongUn ^a   Kang, Dae Gill ^a   Jung, Kwon ^a   Kim, Nam Ho ^a   Suh, Soon Pal ^a   Choi, Ki Chul ^a   Kang, Young Joon ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Erythropoietin; Hypertension; Nitric Oxide; Renal Failure, Chronic

Indexed keywords

ACETYLCHOLINE; ERYTHROPOIETIN; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; NITROPRUSSIDE SODIUM; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANEMIA; ANIMAL; ARTICLE; BLOOD; BODY WEIGHT; CHRONIC KIDNEY FAILURE; DRUG EFFECT; ENZYMOLOGY; KIDNEY; MALE; METABOLISM; MUSCLE ISOMETRIC CONTRACTION; PHYSIOLOGY; RAT; RENOVASCULAR HYPERTENSION; SPRAGUE DAWLEY RAT; THORACIC AORTA; URINE; VASOCONSTRICTION;

ACETYLCHOLINE; ANEMIA; ANIMALS; AORTA, THORACIC; BODY WEIGHT; ERYTHROPOIETIN; HYPERTENSION, RENAL; ISOMETRIC CONTRACTION; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; NITRATES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITES; NITROPRUSSIDE; RATS; RATS, SPRAGUE-DAWLEY; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 0034168287     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2000.15.2.183     Document Type: Article

References (21)

1. Canadian Erythropoietin Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. Br Med J 1990; 300: 573-8.
2. Abraham PA, Macres MG. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol 1991; 2: 927-36.
3. Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW. Hypertension following erythropoietin therapy in anemic hemodialysis patients. Am J Hypertens 1990; 3: 947-55.
4. Raine AE, Roger SD. Effects of erythropoietin on blood pressure. Am J Kidney Dis 1991; 18: 76-83.
5. Martin J, Moncada S. Blood pressure, erythropoietin and nitric oxide. Lancet 1988; 1: 644.
6. Muntzel M, Hannedouche T, Lacour B, Drueke T. Effect of erythropoietin on hematocrit and blood pressure in normotensive and hypertensive rats. J Am Soc Nephrol 1992; 3: 182-7.
7. Wilcox CS, Deng X, Doll AH, Snellen H, Welch WJ. Nitric oxide mediates renal vasodilatation during erythropoietin-induced polycythemia. Kidney Int 1993; 44: 430-5.
8. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Ann Biochem 1976; 72: 248-54.
9. Aiello S, Noris M, Todeschini M, Zappella S, Foglieni C, Benigni A, Coma D, Zoja C, Cavallotti D, Remuzzi G. Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney Int 1997; 50: 171-81.
10. Vaziri ND, Ni Z, Wang XG, Oveisi F, Zhou XJ. Down regulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH. Am J Physiol 1998; 274: F642-9.
11. MacAllister RJ, Whitley GSJ, Vallance P. Effect of guanidino and uremic toxins on nitric oxide systems. Kidney Int 1994; 45: 737-42.
12. Ashab I, Peer G, Blum M, Wollman Y, Chernihovsky T, Hassner A, Schwartz D, Cabili S, Silverberg D, Iaina A. Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int 1995; 47: 1515-21.
13. Reyes AA, Purkerson ML, Karl I, Klahr S. Dietary supplementation with L-arginine ameriolates the progression of the renal disease in rats with subtotal nephrectomy. Am J Kidney Dis 1992; 20: 168-76.
14. Casati S, Passerini P, Campise MR, Graziani G, Cesana B, Perisic M, Ponticelli C. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J Clin Res Ed 1987; 295: 1017-20.
15. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end stage renal disease with recombinant human erythropoietin. N Engl J Med 1987; 316: 73-8.
16. Goretski J, Hollocher TC. Trapping of nitric oxide produced during denitrification by extracellular hemoglobin. J Biol Chem 1988; 263: 2316-23.
17. del Castillo D, Raij L, Shultz PJ, Tolins JP. The pressor effect of recombinant human erythropoietin is not due to decreased activity of the endogenous nitric oxide system. Nephrol Dial Transplant 1995; 10: 505-8.
18. Tsukahara H, Hiraoka M, Hori C, Hata I, Okada T, Gejyo F, Sudo M. Chronic erythropoietin treatment enhances endogenous nitric oxide production in rats. Scand J Clin Lab Invest 1997; 57: 487-93.
19. Buga GM, Gold ME, Fukuto JM, Ignarro LJ. Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension 1991; 17: 187-93.
20. Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res 1994; 74: 349-53.
21. Ongil SL, Saura M, Lamas S, Puyol MR, Puyol DR. Recombinant human erythropoietin does not regulate the expression of endothelin-1 and constitutive nitric oxide synthase in vascular endothelial cells. Exp Nephrol 1996; 4: 37-42.